These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38410023)

  • 1. Efficacy and Safety of IDegAsp in a Real-World Korean Population with Type 2 Diabetes Mellitus.
    Kang S; Ahn YB; Oh TK; Lee WY; Chun SW; Bae B; Dahaoui A; Jeong JS; Jung S; Jang HC
    Diabetes Metab J; 2024 Feb; ():. PubMed ID: 38410023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial.
    Cho KY; Nakamura A; Oba-Yamamoto C; Tsuchida K; Yanagiya S; Manda N; Kurihara Y; Aoki S; Atsumi T; Miyoshi H
    Diabetes Metab J; 2020 Aug; 44(4):532-541. PubMed ID: 31769240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the efficacy and safety of once-daily insulin degludec/insulin aspart (IDegAsp) and long-acting second-generation basal insulin (insulin degludec and insulin glargine 300 units/mL) in insulin-naïve Japanese adults with type 2 diabetes: a pilot, randomized, controlled study.
    Shimoda S; Sakamoto W; Hokamura A; Matsuo Y; Sekigami T; Ichimori S; Iwashita S; Ishii N; Otsu K; Yoshimura R; Nishiyama T; Sakaguchi M; Nishida K; Araki E
    Endocr J; 2019 Aug; 66(8):745-752. PubMed ID: 31308304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensification of IDegAsp Twice Daily (Adding Insulin Aspart vs. Switching To Basal-Bolus): Exploratory Randomized Trial in Type 2 Diabetes.
    Bebakar WM; Chaykin L; Hersløv ML; Rasmussen S
    Diabetes Ther; 2017 Feb; 8(1):197-205. PubMed ID: 27853981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Real-World, Prospective, Non-interventional Study of Adults with T2D Switching to IDegAsp from Glargine U100 or U300 in Japan.
    Shigiyama F; Liu L; Nordahl H; Suzuki R; Yamamoto Y; Hirose T
    Diabetes Ther; 2021 Sep; 12(9):2405-2421. PubMed ID: 34304385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
    Kaneko S; Chow F; Choi DS; Taneda S; Hirao K; Park Y; Andersen TH; Gall MA; Christiansen JS;
    Diabetes Res Clin Pract; 2015 Jan; 107(1):139-47. PubMed ID: 25498130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes.
    Jang HN; Yang YS; Lee SO; Oh TJ; Koo BK; Jung HS
    Endocrinol Metab (Seoul); 2019 Dec; 34(4):382-389. PubMed ID: 31884738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low fasting glucose-to-estimated average glucose ratio was associated with superior response to insulin degludec/aspart compared with basal insulin in patients with type 2 diabetes.
    Jang HN; Yang YS; Oh TJ; Koo BK; Lee SO; Park KS; Jang HC; Jung HS
    J Diabetes Investig; 2022 Jan; 13(1):85-93. PubMed ID: 34291584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes: A Real-World, Prospective, Non-interventional Study Across Six Countries.
    Fulcher GR; Akhtar S; Al-Jaser SJ; Medina J; Mohamed M; Nicodemus NA; Olsen AH; Singh KP; Kok A
    Adv Ther; 2022 Aug; 39(8):3735-3748. PubMed ID: 35752730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of switching from basal-bolus insulin therapy to twice-daily insulin degludec/insulin aspart co-formulation plus insulin aspart in patients with poorly controlled type 2 diabetes.
    Güneş E; Güneş M
    Eur Rev Med Pharmacol Sci; 2023 Jul; 27(14):6691-6699. PubMed ID: 37522680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial.
    Fulcher GR; Christiansen JS; Bantwal G; Polaszewska-Muszynska M; Mersebach H; Andersen TH; Niskanen LK;
    Diabetes Care; 2014 Aug; 37(8):2084-90. PubMed ID: 24812432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST
    Hirsch IB; Franek E; Mersebach H; Bardtrum L; Hermansen K
    Diabet Med; 2017 Feb; 34(2):167-173. PubMed ID: 26773446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of a fixed combination of insulin degludec/insulin aspart in children and adolescents with type 1 diabetes: A randomized trial.
    Battelino T; Deeb LC; Ekelund M; Kinduryte O; Klingensmith GJ; Kocova M; Kovarenko M; Shehadeh N
    Pediatr Diabetes; 2018 Nov; 19(7):1263-1270. PubMed ID: 30014589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial.
    Onishi Y; Yamada K; Zacho J; Ekelund J; Iwamoto Y
    J Diabetes Investig; 2017 Mar; 8(2):210-217. PubMed ID: 27560769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Experience of our Center in Patients Undergoing Insulin Degludec/ Insulin Aspart Co-formulation Therapy.
    Altay FP; Farzaliyeva A; İyidir ÖT; Bozkuş Y; Kırnap NG; Kut A; Nar A; Tütüncü NB
    Endocr Metab Immune Disord Drug Targets; 2023; 23(6):826-831. PubMed ID: 36424790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns.
    Demir T; Turan S; Unluhizarci K; Topaloglu O; Tukek T; Gogas Yavuz D
    Front Endocrinol (Lausanne); 2021; 12():616514. PubMed ID: 33776914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors that affect the Glycemic Control Achieved by Switching to Insulin Degludec/ Aspart in Insulin-Treated Patients with Type 1 and Type 2 Diabetes in a Real-World Setting: a Non-interventional, Retrospective Cohort Study.
    Onder CE; Kuşkonmaz SM; Koc G; Firat S; Omma T; Taskaldiran I; Gokbulut P; Culha C
    Acta Endocrinol (Buchar); 2020; 16(4):443-448. PubMed ID: 34084235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Safety and Clinical Outcomes with Insulin Degludec/Insulin Aspart Treatment in Japanese Patients with Diabetes: A Real-World, Prospective, Observational Study.
    Katabami T; Eriksen KT; Yamamoto Y; Ishigaki Y
    Adv Ther; 2022 Jan; 39(1):544-561. PubMed ID: 34800283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes in Malaysia: Results from a Prospective, Non-interventional Real-World Study.
    Mohamed M; Lim SC; Mumtaz M; Uppal S; Mukherjee D; Kassim MSM; Sreedharan S; Doraiswamy AM; Chong KM; Tat LY; Nordin SB; Giek JLH; Hussein Z; Kadir KA; Lau BK; Chan SP
    J ASEAN Fed Endocr Soc; 2023; 38(1):37-44. PubMed ID: 37252419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial.
    Rodbard HW; Cariou B; Pieber TR; Endahl LA; Zacho J; Cooper JG
    Diabetes Obes Metab; 2016 Mar; 18(3):274-80. PubMed ID: 26592732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.